News & Events about Revance Therapeutics Inc.
Revance Therapeutics, Inc. (NASDAQ:RVNC Get Rating) President Dustin S. Sjuts sold 21,508 shares of the companys stock in a transaction that occurred on Thursday, March 9th. The stock was sold at an average price of $31.59, for a total value of $679,437.72. Following the sale, the president now owns...
Facial Injectable Global Market Report 2022: Sector to Reach $23.55 Billion by 2027 at a 15.46% CAGR Facial Injectable Global Market Report 2022: Sector to Reach $23.55 Billion by 2027 at a 15.46% CAGR PR Newswire DUBLIN, Feb. 28, 2023 DUBLIN, Feb. 28, 2023 /PRNewswire/ -- The 'Facial...
Business Wire
3 months ago
Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the 43rd Annual Cowen Healthcare Conference, taking place March 6-8, 2023, in Boston, Massachusetts. President, Dustin S. Sjuts, and Chief Financial Officer, Tobin Schilke, are scheduled to participate in a...
Business Wire
3 months ago
Revance Therapeutics, Inc. (RVNC) today announced that new data on DAXXIFY will be presented at the annual meeting of Association of Academic Physiatrists (AAP), taking place in Anaheim, California, February 21-24, 2023. The supplemental biologics license agreement for DAXXIFY for the treatment of...
Ticker Report
3 months ago
StockNews.com lowered shares of Revance Therapeutics (NASDAQ:RVNC Get Rating) from a hold rating to a sell rating in a report issued on Thursday. RVNC has been the topic of several other reports. Barclays boosted their price target on Revance Therapeutics from $35.00 to $37.00 and gave the ...